anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic hepatitis B virus (HBV) infection affects 300 million patients worldwide1,2, in whom virus-specific CD8 T cells by still ill-defined mechanisms lose their function and cannot eliminate HBV-infected hepatocytes3-7. Here we demonstrate that a liver immune rheostat renders virus-specific CD8 T cells refractory to activation and leads to their loss of effector functions. In preclinical models of persistent infection with hepatotropic viruses such as HBV, dysfunctional virus-specific CXCR6+ CD8 T cells accumulated in the liver and, as a characteristic hallmark, showed enhanced transcriptional activity of cAMP-responsive element modulator (CREM) distinct from T cell exhaustion. In patients with chronic hepatitis B, circulating and intrahepatic HBV-specific CXCR6+ CD8 T cells with enhanced CREM expression and transcriptional activity were detected at a frequency of 12-22% of HBV-specific CD8 T cells. Knocking out the inhibitory CREM/ICER isoform in T cells, however, failed to rescue T cell immunity. This indicates that CREM activity was a consequence, rather than the cause, of loss in T cell function, further supported by the observation of enhanced phosphorylation of protein kinase A (PKA) which is upstream of CREM. Indeed, we found that enhanced cAMP-PKA-signalling from increased T cell adenylyl cyclase activity augmented CREM activity and curbed T cell activation and effector function in persistent hepatic infection. Mechanistically, CD8 T cells recognizing their antigen on hepatocytes established close and extensive contact with liver sinusoidal endothelial cells, thereby enhancing adenylyl cyclase-cAMP-PKA signalling in T cells. In these hepatic CD8 T cells, which recognize their antigen on hepatocytes, phosphorylation of key signalling kinases of the T cell receptor signalling pathway was impaired, which rendered them refractory to activation. Thus, close contact with liver sinusoidal endothelial cells curbs the activation and effector function of HBV-specific CD8 T cells that target hepatocytes expressing viral antigens by means of the adenylyl cyclase-cAMP-PKA axis in an immune rheostat-like fashion.
In the CLL2-BCG-trial, a total of 62 patients of an allcomer CLL population (irrespective of physical fitness, previous therapies and prognostic factors) with an indication for treatment will be included. Patients will receive 2 cycles of debulking treatment with bendamustine unless contraindications (e.g. refractoriness) are present or a debulking is not indicated due to a low tumor burden. Afterwards, 6 cycles of induction treatment with GA101 (obinutuzumab, 3 doses in the first cycle and monthly in cycles 2-6) and CAL-101 (idelalisib, continuously starting in cycle 2) will be applied. The primary endpoint overall response rate will be assessed at final restaging (2 months after end of induction treatment). Patients benefitting from treatment receive further therapy with GA101 (3 monthly) and CAL-101 (continuously) in a maintenance phase for up to 24 months. Maintenance treatment will be stopped in case of achievement of a complete remission and confirmation of MRD (minimal residual disease) negativity in peripheral blood or if unacceptable toxicity or progression occurs.
Techniques for granular analysis of a knowledge graph are provided. A profile comprising a plurality of attributes is received, and a knowledge graph is analyzed to identify a plurality of therapies, based on the plurality of attributes. A document that is relevant to a first therapy of the plurality of therapies is identified, and a criterion stated in the document is determined. Further, an aggregate value is determined for the criterion, based on a plurality of participants associated with the document, wherein the first aggregate value represents attributes of the plurality of participants. A weight is generated for the document, based at least in part on the plurality of attributes and the aggregate value. A score is generated for the first therapy, based at least in part on the weight, and an optimal therapy is determined, from the plurality of therapies, based in part on the score.
This group includes young adults aged 18-25 who do not exhibit temporomandibular joint (TMJ) dysfunction. Participants in this group have a Fonseca Amnestic Index score of 20 or lower. Similar to the TMJ dysfunction group, these participants are being evaluated for proprioception, body awareness, and pain-related parameters such as pain threshold, pain tolerance, and temporal summation.
I present a method to allocate a given number of vaccines to members of a population who differ in their susceptibility to the disease so that the final size of the epidemic is minimised. I consider an arbitrary distribution of protection that the vaccine confers, including the extreme cases of leaky and all-or-none vaccines. The optimal vaccination policy depends on the distribution of protection. While for low values of the basic reproduction number R0 the optimal policy prioritises the most susceptible hosts, I show that for almost any distribution the order of priority reverses and the least susceptible hosts should be vaccinated when R0 is high. The exception where this does not happen is the all-or-none vaccine. However, even a small deviation from the ideal all-or-none distribution can imply that the limited number of vaccines should be given to less susceptible hosts already at realistic values of R0.
An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments. In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.
BACKGROUND: This prospective study aimed to evaluate the outcomes of the use of dermal templates for lengthy volar soft tissue defects (1.5-4 cm) in the fingers.
METHODS: The volar soft tissue defects of 15 patients (19 fingers) were treated with Lando dermal template coverage between June 2022 and November 2022. We evaluated sensory recovery, scar formation, and overall appearance of the repair site at an average of 13 months (range, 12-17 months) of follow-up.
RESULTS: The defect healed in all cases. We found an average static 2-point discrimination of 7 mm (range 4 to 14 mm). Scar formation was evident in all cases. The repair did not restore the bulkiness of the volar finger, especially in the finger with the bony exposure. Nail deformities and joint contracture were observed in some cases.
CONCLUSION: Dermal template repair does not restore normal sensation and inevitably leads to scar formation when the defect is longer (>1.5 cm). Bulkiness of the volar finger is not restored in most patients, especially when there was bone or tendon exposure in the initial wound site.
The Advanced Trauma Life Support (ATLS) approach is generally accepted as the standard of care for the initial management of severely injured patients. While whole body computed tomography (WBCT) is still considered a contraindication in haemodynamically unstable trauma patients, there is a growing amount of data indicating the absence of harm from cross sectional imaging in this patient group. Our study aimed to compare the early mortality of unstable trauma patients undergoing a WBCT during the initial workup with those who did not. Single-center retrospective observational study based on the local trauma registry including 3525 patients with an ISS > 15 from January 2008 to June 2020. We compared the 24-h mortality of injured patients in circulatory shock undergoing WBCT with a control group undergoing standard workup only. Inclusion criteria were the simultaneous presence of a systolic blood pressure < 100 mmHg, lactate > 2.2 mmol/l and base excess < - 2 mmol/l as surrogate markers for circulatory shock. To control for confounding, a propensity score matched analysis with conditional logistic regression for adjustment of residual confounders and a sensitivity analysis using inverse probability weighting (IPW) with and without adjustment were performed. Of the 3525 patients, 161 (4.6%) fulfilled all inclusion criteria. Of these, 132 (82%) underwent WBCT and 29 (18%) standard work-up only. In crude and matched analyses, no difference in early (24 h) mortality was observed (WBCT, 23 (17.4%) and no-WBCT, 8 (27.6%); p = 0.21). After matching and adjustment for main confounders, the odds ratio for the event of death at 24 h in the WBCT group was 0.36 (95% CI 0.07-1.73); p = 0.20. In the present study, WBCT did not increase the risk of death at 24 h among injured patients in shock. This adds to the growing data indicating that WBCT may be offered to trauma patients in circulatory shock without jeopardizing early survival.
The invention aims to provide a nanofiber reinforced resin-based photocuring repair material and a preparation method thereof. The fiber is used as an important reinforcement of the composite material, and has the advantages of improving the strength and modulus of the light-cured resin, reducing the curing shrinkage of the material and the like in the application of dental repair materials. The invention adopts the melt spinning technology to prepare the nano-fiber,the light-cured repair material is prepared as a component of a polymer repair material. The addition of the nano-fiber improves the tensile strength and the breaking strength of the composite material, and greatly reduces the deformation and cracking of the cured product. By adopting a photocuring mode and using a composite photo-initiation system, the curing speed and the curing completion rate are improved, and the storage stability of the product is improved. The water absorption rate of the cured nanofiber reinforced resin-based repair material is less than 30 mu g/mm 3 The flexural strength is more than 185Mpa, the elastic modulus is between 1.7 and 3.6Gpa, and the surface friction resistance is unchanged for 8 ten thousand times.
PCT No. PCT/US96/03435 Sec. 371 Date Sep. 12, 1997 Sec. 102(e) Date Sep. 12, 1997 PCT Filed Mar. 13, 1996 PCT Pub. No. WO96/28167 PCT Pub. Date Sep. 19, 1996This invention relates to compositions comprising nicotinylalanine (NAL) and/or related analogues, and an inhibitor of glycine conjugation, either synthetic or naturally occurring. Vitamin B6 may also be present in the compositions of this invention in place of, or in addition to, the inhibitor of glycine conjugation. The compositions may be pharmaceutical in nature. The compositions are useful for inhibiting cellular poly(ADP-ribose) polymerase (PARP, PARS, poly(ADP-ribose) synthetase), an enzyme which causes cellular toxicity and which is activated in a variety of toxic and pathological conditions. PARP is inhibited by some metabolites of the tryptophan oxidative pathway, including nicotinamide, kynurenic acid and xanthurenic acid, which are induced by interferon-gamma. The NAL-containing compositions of the invention enhance the intracellular levels of these metabolites, and thereby augment the natural defense of interferon-induced inhibition of PARP. PARP is implicated in various pathological conditions, including neurodegenerative disorders, viral infections such as AIDS, autoimmune diseases and cancer. Accordingly, this invention also relates to methods of reducing cellular toxicity, and treating or preventing such diseases, by increasing cellular concentrations of nicotinamide, kynurenic acid and xanthurenic acid using the compositions of this invention.
On average, one third of a woman's life passes during menopause. The menopausal period is an important period that brings many physical and psychological changes with it and significantly affects the disease process and the family and society. Cultural and ethnic characteristics of the society are among the important factors that affect women's attitudes towards menopause and the meaning of middle age for women.women seek ways to deal with menopausal symptoms.

women prefer drug-free coping methods. Mindfulness stress reduction program, yoga and laughter yoga are an alternative way to reduce menopausal symptoms.. These methods can reduce the complaints and increase the quality of life. For this reason, the effect should be determined in the menopausal period.
To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
BACKGROUND: Cognitive frailty, defined as having both physical frailty and cognitive impairment that does not satisfy the criteria for Major Neurocognitive Disorder, represents an elevated risk for morbidity. Hence, it is crucial to mitigate such risks. Physical activity interventions have been found effective in protecting against physical frailty and cognitive deterioration. This pilot RCT examines if smartwatches and mobile phone applications can help to increase physical activity, thereby improving physical and cognitive outcomes.
METHODS: Older individuals (n = 60) aged 60 to 85 years old will have their physical activity tracked using a smartwatch. The subjects will be randomized into two arms: one group will receive daily notification prompts if they did not reach the recommended levels of PA; the control group will not receive prompts. Outcome variables of physical activity level, neurocognitive scores, and physical frailty scores will be measured at baseline, T1 (3 months), and T2 (6 months). Sleep quality, levels of motivation, anxiety, and depression will be controlled for in our analyses. We hypothesize that the intervention group will have higher levels of physical activity resulting in improved cognitive and physical outcomes at follow-up. This study was approved by the National University of Singapore's Institutional Review Board on 17 August 2020 (NUS-IRB Ref. No.: H-20-038).
DISCUSSION: Wearable sensors technology could prove useful by facilitating self-management in physical activity interventions. The findings of this study can justify the use of technology in physical activity as a preventive measure against cognitive frailty in older adults. This intervention also complements the rapidly rising use of technology, such as smartphones and wearable health devices, in our lives today.
REGISTRATION DETAILS: This study has been retrospectively registered on clinicaltrials.gov on 5th January 2021 (NCT Identifier: NCT04692974), after the first participant was recruited.
The invention discloses a siRNA molecule for inhibiting HIST1H2BD gene, which consists of a sense strand with the sequence of SEQ ID NO. 1 and an antisense strand with the sequence of SEQ ID NO. 2; or a sense strand with the sequence SEQ ID NO. 3 and an antisense strand with the sequence SEQ ID NO. 4. The siRNA molecule can induce the apoptosis of human esophageal cancer cells TE-1 and EC9706 and inhibit the proliferation, growth and clone forming ability of the esophageal cancer cells, so that the siRNA molecule can be used for preparing an esophageal cancer treatment drug.
Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities.
PURPOSE:To obtain a hair growth stimulant which is an edible or a drinkable article capable of lightly growing the hair such as hair of the head by oral administration. CONSTITUTION:This hair growth stimulant consists essentially of an equine tooth or its extract. The equine tooth consisting essentially of baked and powdered one is readily usable. The equine tooth is processed by separating the equine tooth from the equine cranial bone, washing the separated equine tooth, baking the washed equine tooth, then pulverizing the baked tooth, grinding and powdering the pulverized tooth and preparing the equine tooth powder. Hair roots are thickened by ingesting the equine tooth to change the scalp into the goose-skin. Thereby, black hair is provided.
Vitiligo is a chronic depigmentation disorder characterized by well-demarcated white macules and patches, reflecting selective melanocyte destruction. Hyperpigmentation at the treated areas is one of the limitations of phototherapy. Topical tretinoin (retinoic acid) has been well established to be effective for skin pigmentary disorders including melasma. This study aims to investigate the preventive effect of topical tretinoin on hyperpigmentation during phototherapy. A randomized controlled trial based on split-face was planned. The left/right face will be randomized to either tretinoin or placebo cream treatment groups. All lesions will be treated using phototherapy twice weekly for a total of 12-week period. The degree of repigmentation will be assessed as % from baseline by using a computer program every 4 weeks.
PURPOSE: A pharmaceutical composition containing a conditioned medium prepared by three dimensional culture is provided to regenerate blood vessel in ischemic vascular diseases and to effectively treat ischemic vascular diseases. CONSTITUTION: A pharmaceutical composition for treating ischemic diseases contains conditioned medium as an active ingredient, prepared by three-dimensional culture of adult stem cells using a culture medium. The adult stem cells are adipose-derived stem cells, umbilical cord blood-derived stem cells, or bone marrow stem cells. The adult stem cells are cultured in a hypoxic condition. The buffer solution is 4-(2-hydroxy ethyl)-1-piperazine ethane sulfonic acid(HEPES) buffer solution. A cosmetic composition for preventing or treating alopecia and wrinkling contains the conditioned medium as an active ingredient. [Reference numerals] (AA) Secretion of angiogenic factor per cell(pg/10^5 cells); (BB) Concentration of cells in medium(1x10^5 cells/ml); (CC) Concentration of growth factors in medium(pg/ml)
Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular diseases). Approximately 50% of HIV-infected patients are regular tobacco smokers. Tobacco smoking cessation has well known benefits on mortality and morbidity in the general population where tobacco cessation assistance programs are increasingly implemented. However, smoking cessation interventions have never been evaluated among HIV-infected patients. This trial aims at evaluating the efficacy and safety of varenicline for smoking cessation compared with placebo. A pharmacokinetic study will be conducted to evaluate the effect of smoking cessation on the plasma concentration of antiretroviral treatment.
The study is based on the carbon oxidation protocol. Each baby will receive one or two levels of either phenylalanine or methionine or histidine. Each level will be assessed over a two-day period.

On day 1: each baby will receive a standard pediatric amino acid solution, Primene used in the NICU and L-\[1-13C\]Na Bicarbonate will be given to measure carbon dioxide production. On day 2: he/she will receive the appropriate TPN Test Solution made up of the appropriate Bulk Amino Acid solution (for Phenylalanine/ Methionine/ Histidine Studies) with a different amount of the amino acid being investigated. To see how these amino acids are used in the body the investigators will add a small amount (calculated based on the body weight of the baby) of the amino acid L-\[1-13C\]phenylalanine to the amino acid solution. Breath and urine will be collected from the baby to study the oxidation of the L -\[1-13C\]phenylalanine. The investigators will take 2 x 0.75 ml blood to measure plasma amino acid concentration. The investigators will aim to coordinate blood taking with regular blood work done for clinical monitoring.
This is a single blinded randomized controlled trial, will be conducted at Pakistan railway general hospital Rawalpindi. Both MWM and Mulligan knee taping Techniques are used in patients with patellofemoral pain syndrome. Sample size of 34 individuals was calculated through Open Epi tool version 3 with 95 % confidence interval (CI), and power 80%. 34 individuals were screened out on the basis of inclusion and exclusion criteria. Individuals of this selected population were randomly allocated as 17 individuals in MWM (straight leg raise with traction and tibial gliding) group and 17 individuals Mulligan knee taping group by sealed envelope method. And after this Both groups will receive conventional therapy.

Assesment will be done at baseline, 2nd week and after 6 weeks Data will be analyzed on SPSS version 21.
This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
The lower bone mineral density that has been described in patients with HIV-infection has not meant an increase of long term complications. Nevertheless, it could involve an increase if the associated co-mordibity in the future, taking in care that in general population osteoporosis increases 4 times the pathologic fracture risk. That's why it is necessary to know the real prevalence of osteoporosis in this population of patients so the real dimensions of the problems can be defined.

This project wills to determine the incidence of osteoporosis in our population of HIV-infected patients and to assess the efficacy and security of ibandronate, whose efficacy in post-menopausal women has been already proved. If the quarterly use of endovenous ibandronate obtains equivalent results to those obtained with oral and weekly alendronate in other studies with the same population, its use would be justified because of its posology benefits. The monthly or quarterly administration can improve compliance in patients who are recieving a big quantity of drugs, as HIV infected patients do and who probably have to be treated for life. Moreover, its elimination is renal so there is absence of interactions with antiretroviral drugs what mades of ibandronate a very promising alternative. Finally, there's no risk of digestive intolerance because of its parenteral administration and it has a better posology than oral bifosfonates.